e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Pathobiology of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Signs of MICA as an innate immune molecule potentially involved in vascular remodelling in patients with pulmonary hypertension
M. Orozco-Levi, L. Molina, V. Peinado, A. Ramirez-Sarmiento, V. Curull, L. Pijuan, B. Casado, F. Miranda, B. Vaquerizo, A. Serra, J. Gea, J. A. Barbera (Barcelona, Spain)
Source:
Annual Congress 2010 - Pathobiology of pulmonary hypertension
Session:
Pathobiology of pulmonary hypertension
Session type:
Thematic Poster Session
Number:
1091
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Orozco-Levi, L. Molina, V. Peinado, A. Ramirez-Sarmiento, V. Curull, L. Pijuan, B. Casado, F. Miranda, B. Vaquerizo, A. Serra, J. Gea, J. A. Barbera (Barcelona, Spain). Signs of MICA as an innate immune molecule potentially involved in vascular remodelling in patients with pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1091
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Autoimmunity and pulmonary hypertension: a perspective
Source: Eur Respir J 2005; 26: 1110-1118
Year: 2005
Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017
Soluble ADAM33 augments the pulmonary innate immune response promoting susceptibility to allergic airway inflammation
Source: International Congress 2018 – Translational models of the immunopathology that underlies airway obstructive diseases
Year: 2018
Treg alterations lead to systemic and local immune deregulation in idiopathic pulmonary fibrosis and collagen vascular disease-associated interstitial pneumonia
Source: Annual Congress 2007 - Cell biology of asthma and COPD
Year: 2007
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012
Pulmonary defence mechanisms and inflammatory pathways in bronchiectasis
Source: Eur Respir Mon 2011; 52: 11-21
Year: 2011
The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations
Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity
Year: 2020
Evaluation of specific immune complexes in patients with pulmonary sarcoidosis.
Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management
Year: 2018
Endothelial NO and its pathophysiologic regulation
Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease
Year: 2007
Polymorphisms of innate immune response genes and severe systemic inflammatory response syndromes
Source: Eur Respir J 2006; 28: Suppl. 50, 347s
Year: 2006
The innate immune function of airway epithelial cells in inflammatory lung disease
Source: Eur Respir J 2015; 45: 1150-1162
Year: 2015
Neurokinins contribute to vascular remodelling in a model of chronic pulmonary allergic inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 760s
Year: 2006
The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases
Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Year: 2005
Relevance of innate immune responses to chronic airway diseases
Source: Annual Congress 2008 - The battle between environmental “invaders” and airway epithelial defences
Year: 2008
Microbes mediated host innate immune response in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
HIV-associated pulmonary arterial hypertension onset is associated with the soluble CD14 level and inflammation related to monocyte activation by LPS translocation from the gut
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
Is soluble MICA facilitating tumor immune evasion in patients with COPD?
Source: Annual Congress 2008 - Basic science in asthma and COPD II
Year: 2008
COPD is associated with reduced pulmonary interstitial expression of pentraxin-3
Source: Eur Respir J 2012; 39: 830-838
Year: 2012
Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with
BMPR2
mutation
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept